MET and neoplasm: While the number of METex14 RNA reads indicative of successful therapy with MET inhibitors continues to be unknown, it is essential to gather as much clinical and molecular evidence as possible for those cases with low RNA reads whose tumor profiles did not show actionable nor driver variants, such as the 57% of the patients with low RNA reads for METex14 analyzed here.